Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Fineline Cube Feb 28, 2026
Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Fineline Cube Feb 28, 2026
Company Drug

Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment

Fineline Cube Feb 24, 2025

Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...

Company Deals

Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones

Fineline Cube Feb 24, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...

Company

Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities

Fineline Cube Feb 24, 2025

Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...

Company Drug

Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials

Fineline Cube Feb 24, 2025

China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...

Company Drug

Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials

Fineline Cube Feb 24, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...

Company Drug

Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease

Fineline Cube Feb 24, 2025

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a...

Company Deals

Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights

Fineline Cube Feb 24, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) announced on February 21, 2025, that it plans to...

Company Drug

Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer

Fineline Cube Feb 24, 2025

Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), announced that the U.S....

Company Drug

Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress

Fineline Cube Feb 24, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...

Company Drug

Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy

Fineline Cube Feb 24, 2025

China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical...

Company Drug

J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction

Fineline Cube Feb 24, 2025

U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...

Company Medical Device

MicroPort CardioFlow’s AnchorMan LAA Occluder System Earns CE Mark Approval

Fineline Cube Feb 24, 2025

Hong Kong-listed MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has received the CE mark for...

Company Drug

AIM Vaccine Leverages DeepSeek AI to Optimize mRNA Shingles Vaccine Design

Fineline Cube Feb 24, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has filed its mRNA-based shingles vaccine with the...

Company Drug

Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer

Fineline Cube Feb 24, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National...

Policy / Regulatory

AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments

Fineline Cube Feb 23, 2025

The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent...

Policy / Regulatory

In-Depth Analysis of the National Healthcare Security Policy: A Guide to Key Reforms and Implications

Fineline Cube Feb 22, 2025

The National Healthcare Security Administration (NHSA) has unveiled its 2025 priority action list, focusing on...

Policy / Regulatory

State Council’s Draft Plan Boosts Innovative Drug Development via Medical Insurance Reforms

Fineline Cube Feb 22, 2025

The State Council has released a second draft proposal outlining measures to support the high-quality...

Company Medical Device

Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing

Fineline Cube Feb 22, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing...

Policy / Regulatory

Shanghai Issues Legal Guidebook for Innovative Drug Marketing

Fineline Cube Feb 22, 2025

The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative...

Policy / Regulatory

China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation

Fineline Cube Feb 22, 2025

The Chinese government has released a set of opinions detailing the establishment of a new...

Posts pagination

1 … 170 171 172 … 628

Recent updates

  • Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion
  • Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA
  • Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer
  • Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis
  • Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Company Drug

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Company Drug

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.